Published in Neurology on April 11, 2006
Quality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. Neurology (2010) 2.29
Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trial. Ann Neurol (2009) 2.29
Viral parkinsonism. Biochim Biophys Acta (2008) 1.57
Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol (2010) 1.57
Greater improvement in quality of life following unilateral deep brain stimulation surgery in the globus pallidus as compared to the subthalamic nucleus. J Neurol (2009) 1.45
Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. Neurology (2014) 1.45
Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study. Neurology (2010) 1.43
Deep brain stimulation in early Parkinson's disease: enrollment experience from a pilot trial. Parkinsonism Relat Disord (2011) 1.11
Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J (2007) 1.11
A decision tool to support appropriate referral for deep brain stimulation in Parkinson's disease. J Neurol (2009) 1.07
Attitudes and barriers to clinical practice guidelines in general and to the guideline on Parkinson's disease. A National Survey of German neurologists in private practice. J Neurol (2009) 1.06
Cognitive declines one year after unilateral deep brain stimulation surgery in Parkinson's disease: a controlled study using reliable change. Clin Neuropsychol (2008) 1.05
Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease. Neurobiol Dis (2007) 0.99
Traditional chinese medicine improves activities of daily living in Parkinson's disease. Parkinsons Dis (2011) 0.98
Pilot study assessing the feasibility of applying bilateral subthalamic nucleus deep brain stimulation in very early stage Parkinson's disease: study design and rationale. J Parkinsons Dis (2012) 0.97
Current status of symptomatic medical therapy in Parkinson's disease. Neurotherapeutics (2008) 0.94
Continuous levodopa for advanced Parkinson's disease. Neuropsychiatr Dis Treat (2007) 0.92
Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. PLoS One (2010) 0.92
Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics (2014) 0.92
A tool to improve pre-selection for deep brain stimulation in patients with Parkinson's disease. J Neurol (2010) 0.92
Deep brain stimulation in Parkinson's disease. Ther Adv Neurol Disord (2009) 0.90
The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's disease. J Neural Transm (Vienna) (2010) 0.90
Noninvasive brain stimulation for Parkinson's disease and dystonia. Neurotherapeutics (2008) 0.89
Levodopa-induced dyskinesias and their management. J Neurol (2008) 0.89
Two-year exercise program improves physical function in Parkinson's disease: the PRET-PD randomized clinical trial. Neurorehabil Neural Repair (2014) 0.89
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features. Neuropsychiatr Dis Treat (2008) 0.86
Assessment of Parkinson disease manifestations. Curr Protoc Neurosci (2009) 0.85
Treatment of advanced Parkinson's disease. Curr Opin Neurol (2014) 0.85
Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review. J Neural Transm (Vienna) (2009) 0.84
Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery? J Neural Transm (Vienna) (2013) 0.84
Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats. ACS Chem Neurosci (2013) 0.84
The role of neuroplasticity in dopaminergic therapy for Parkinson disease. Nat Rev Neurol (2013) 0.83
Parkinson's disease. BMJ (2007) 0.83
Stimulation region within the globus pallidus does not affect verbal fluency performance. Brain Stimul (2012) 0.83
Effectiveness of traditional Chinese medicine as an adjunct therapy for Parkinson's disease: a systematic review and meta-analysis. PLoS One (2015) 0.83
Deep brain stimulation of the subthalamic nucleus improves reward-based decision-learning in Parkinson's disease. Front Hum Neurosci (2011) 0.83
Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy? Ther Adv Neurol Disord (2012) 0.82
Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease. Clin Interv Aging (2009) 0.82
Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis. J Parkinsons Dis (2015) 0.82
Metabotropic glutamate receptors for Parkinson's disease therapy. Parkinsons Dis (2013) 0.82
Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBS-PD). Mov Disord (2010) 0.81
Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected]. Neuropharmacology (2011) 0.81
Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline? Neurotherapeutics (2014) 0.80
VBM Reveals Brain Volume Differences between Parkinson's Disease and Essential Tremor Patients. Front Hum Neurosci (2013) 0.79
Deep brain stimulation for the treatment of Parkinson's disease: efficacy and safety. Degener Neurol Neuromuscul Dis (2012) 0.79
Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial. CNS Drugs (2015) 0.79
Update on Deep Brain Stimulation for Dyskinesia and Dystonia: A Literature Review. Neurol Med Chir (Tokyo) (2016) 0.78
The "gender factor" in wearing-off among patients with Parkinson's disease: a post hoc analysis of DEEP study. ScientificWorldJournal (2015) 0.78
Compliance with pharmacotherapy and direct healthcare costs in patients with Parkinson's disease: a retrospective claims database analysis. Appl Health Econ Health Policy (2013) 0.78
Parkinson's Disease and Its Management: Part 4: Treatment of Motor Complications. P T (2015) 0.78
Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease. Curr Neuropharmacol (2016) 0.78
A review of ropinirole prolonged release in Parkinson's disease. Clin Interv Aging (2009) 0.77
The recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's disease. Transl Neurodegener (2016) 0.77
Unusual complications of deep brain stimulation. Neurosurg Rev (2014) 0.77
Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease. Patient Prefer Adherence (2011) 0.77
Current clinical practice for Parkinson's disease among Chinese physicians, general neurologists and movement disorders specialists: a national survey. BMC Neurol (2012) 0.77
Deficits in the Mimicry of Facial Expressions in Parkinson's Disease. Front Psychol (2016) 0.77
Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients. J Neurol (2014) 0.76
Assessment of Treatment Patterns and Patient Outcomes in Levodopa-Induced Dyskinesias (ASTROID): A US Chart Review Study. Am Health Drug Benefits (2012) 0.76
Selegiline shortage: Causes and costs of a generic drug shortage. Neurology (2009) 0.76
Pharmacotherapy in Parkinson's disease: case studies. Ther Adv Neurol Disord (2010) 0.76
Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type-B inhibitor: A Cross-Sectional, Cohort Study. Pharmacotherapy (2015) 0.76
Role of rasagiline in treating Parkinson's disease: Effect on disease progression. Ther Clin Risk Manag (2009) 0.76
Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease. J Neural Transm (Vienna) (2007) 0.76
How to improve patient education on deep brain stimulation in Parkinson's disease: the CARE Monitor study. BMC Neurol (2017) 0.75
Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease. Funct Neurol (2013) 0.75
Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease. Parkinsons Dis (2017) 0.75
Part 2: Introduction to the Pharmacotherapy of Parkinson's Disease, With a Focus on the Use of Dopaminergic Agents. P T (2015) 0.75
Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. Parkinsons Dis (2016) 0.75
Patient considerations in early management of Parkinson's disease: focus on extended-release pramipexole. Patient Prefer Adherence (2012) 0.75
Developing a Deep Brain Stimulation Neuromodulation Network for Parkinson Disease, Essential Tremor, and Dystonia: Report of a Quality Improvement Project. PLoS One (2016) 0.75
Systems-level neurophysiological state characteristics for drug evaluation in an animal model of levodopa-induced dyskinesia. J Neurophysiol (2016) 0.75
Altered Neuronal Firing Pattern of the Basal Ganglia Nucleus Plays a Role in Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease. Front Hum Neurosci (2015) 0.75
Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy. Neurol Clin Pract (2017) 0.75
Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson's Disease. Parkinsons Dis (2016) 0.75
Treatment in late Parkinson's disease. Ann Indian Acad Neurol (2011) 0.75
Utility of tolcapone in fluctuating Parkinson's disease. Clin Interv Aging (2006) 0.75
ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. J Parkinsons Dis (2017) 0.75
Soluble and controlled-release preparations of levodopa: do we really need them? J Neurol (2010) 0.75
Real time quantitative PCR. Genome Res (1996) 35.79
Identification and characterization of the familial adenomatous polyposis coli gene. Cell (1991) 14.46
Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application. Report of an IFCN committee. Electroencephalogr Clin Neurophysiol (1994) 9.41
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Annual deaths attributable to obesity in the United States. JAMA (1999) 8.62
A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell (1990) 8.10
Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell (1990) 6.94
A prospective randomized trial of blastocyst culture and transfer in in-vitro fertilization. Hum Reprod (1998) 6.80
Identification of deletion mutations and three new genes at the familial polyposis locus. Cell (1991) 5.42
The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell (1990) 5.24
Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. Neurology (1997) 4.93
International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci (1997) 4.50
Activation of the primary visual cortex by Braille reading in blind subjects. Nature (1996) 3.91
Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer. Fertil Steril (2000) 3.60
Responses to rapid-rate transcranial magnetic stimulation of the human motor cortex. Brain (1994) 3.57
AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol (2008) 3.54
Surgery on the rheumatoid cervical spine for the non-ambulant myelopathic patient-too much, too late? Lancet (1996) 3.52
Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol Cell (2001) 3.34
Modulation of muscle responses evoked by transcranial magnetic stimulation during the acquisition of new fine motor skills. J Neurophysiol (1995) 3.27
Rapid plasticity of human cortical movement representation induced by practice. J Neurophysiol (1998) 3.26
Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell (1992) 3.20
A physiological mechanism of bradykinesia. Brain (1980) 3.15
Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2007) 3.12
Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial. Am J Psychiatry (1997) 3.02
Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord (2002) 3.00
Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2004) 2.93
Dose standardisation of botulinum toxin. Lancet (1989) 2.83
Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2002) 2.81
Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA (2001) 2.79
The problem-orientated medical record in general practice. J R Coll Gen Pract (1973) 2.77
Practice parameter: Assessing patients in a neurology practice for risk of falls (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2008) 2.77
Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2006) 2.77
Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2003) 2.76
EMG analysis of stereotyped voluntary movements in man. J Neurol Neurosurg Psychiatry (1975) 2.71
Clinical evaluation of idiopathic paroxysmal kinesigenic dyskinesia: new diagnostic criteria. Neurology (2004) 2.70
Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology (2006) 2.70
Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology (2002) 2.68
Spinal motor neuron excitability during the silent period after cortical stimulation. Electroencephalogr Clin Neurophysiol (1991) 2.68
The pathophysiology of primary dystonia. Brain (1998) 2.51
Effect of GPi pallidotomy on motor function in Parkinson's disease. Lancet (1995) 2.47
Modulation of cortical motor output maps during development of implicit and explicit knowledge. Science (1994) 2.41
Periodic emission from the gamma-ray binary 1FGL J1018.6-5856. Science (2012) 2.40
Optimal focal transcranial magnetic activation of the human motor cortex: effects of coil orientation, shape of the induced current pulse, and stimulus intensity. J Clin Neurophysiol (1992) 2.38
Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA (2001) 2.36
Functional relevance of cross-modal plasticity in blind humans. Nature (1997) 2.36
Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2003) 2.35
Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain (2009) 2.35
Quality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. Neurology (2010) 2.29
Human motor evoked responses to paired transcranial magnetic stimuli. Electroencephalogr Clin Neurophysiol (1992) 2.27
Pathophysiology of bradykinesia in Parkinson's disease. Brain (2001) 2.24
Feedforward ankle strategy of balance during quiet stance in adults. J Physiol (1999) 2.24
Superglue inadvertently used as eyedrops. BMJ (1990) 2.17
Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2005) 2.16
Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology (1993) 2.16
Factors which influence mortality after subcapital hip fracture. J Bone Joint Surg Br (1992) 2.11
Nervous system reorganization following injury. Neuroscience (2002) 2.11
Magnetic stimulation: motor evoked potentials. The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol Suppl (1999) 2.10
Ballistic flexion movements of the human thumb. J Physiol (1979) 2.06
Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport (1995) 2.06
Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology (2003) 2.04
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol (2013) 2.04
Cognitive planning deficit in patients with cerebellar atrophy. Neurology (1992) 2.03
Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol (2011) 1.98
Changes in risk factors for cardiovascular disease by baseline weight status in young adults who maintain or gain weight over 15 years: the CARDIA study. Int J Obes (Lond) (2006) 1.96
Prediction equations do not eliminate systematic error in self-reported body mass index. Obes Res (1997) 1.94
Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol. Fertil Steril (1997) 1.93
Human corticospinal excitability evaluated with transcranial magnetic stimulation during different reaction time paradigms. Brain (2000) 1.91
Mutational analysis of the redox-sensitive transcriptional regulator OxyR: regions important for DNA binding and multimerization. J Bacteriol (1995) 1.89
Neural networks for Braille reading by the blind. Brain (1998) 1.88
Mechanisms of deafferentation-induced plasticity in human motor cortex. J Neurosci (1998) 1.88
Prediction of survival in patients with femoral neck fractures. J Bone Joint Surg Br (1987) 1.87
Periodic limb movements in sleep: state-dependent excitability of the spinal flexor reflex. Neurology (2000) 1.83
Mesial motor areas in self-initiated versus externally triggered movements examined with fMRI: effect of movement type and rate. J Neurophysiol (1999) 1.83
A prospective study of coronary heart disease in relation to fasting insulin, glucose, and diabetes. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care (1997) 1.82